Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in a recent “Bell2Bell” podcast episode in which CEO Hector Bremner discussed the company’s history, its goals and the plans it has for development further down the road. “Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from tests not only with the patient but also with medical professionals and researchers without compromising health privacy,” reads a recent article. Avricore accomplished the initial rollout by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada. The company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom. Avricore is excited about opportunities in the United Kingdom and EU, a market bigger than China. “Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics.”
To view the full article, visit https://ibn.fm/FAhWT
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM), (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
